Antibody drug conjugates for cancer therapy: where we are and what lies ahead?
• In the last year, four ADCs have been approved for cancer therapy, and many others are in advanced-stage clinical trials
• Isolation of 403 monoclonal antibodies from COVID-19 patients yielded 19 potently neutralizing antibodies against SARS-CoV-2
• An overview of the field will be provided and the challenges that lie ahead will be discussed
VP, Distinguished Research Fellow